In older patients with EGFR mutation-positive lung cancer who received EGFR-TKIs, the incidence of drug-induced ILD was significantly increased during osimertinib treatment compared with treatment with other EGFR-TKIs. This evidence concerns the gene EGFR and interstitial lung disease.